Iovance Biotherapeutics, Inc.
NASDAQ:IOVABiotechnology
-$0.04 today
- Market cap
- $3.46B
- Beta
- 0.70
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.85
Volume 6.99M
Average 14.09M
IOVA Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Iovance Biotherapeutics, Inc.NASDAQ: IOVA
Revenue · Q3 FY2026 · quarter ended Sep 2026
Revenue growth accelerates
Q3 FY2026 revenue of $121.47M rose 80.1% year over year, ahead of the +51.3% change in trailing-twelve-month revenue. Sequentially, it rose 22.3% from the prior quarter.
Context
- Revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 5 analysts of $418.98M (+59.0%) for the fiscal year ending Dec 2026, a slowdown from the +60.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $121.47M+22.3% QoQ
- Last fiscal yearDec 2025
- $263.5M+60.6% YoY
- LTMSep 2026
- $378.98M+51.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +80.1% | +48.2% | -31.9 pp |
| 1 year | +60.6% | +59.0% | -1.6 pp |
| 3-year CAGR | — | +49.8% | — |
| 5-year CAGR | +40.9% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 263.5M USD
- Year-over-year change
- +60.6%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 263.5M | +60.6% |
| FY2024 | 2024-12-31 | 164.07M | +13699.0% |
| FY2023 | 2023-12-31 | 1.19M | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Revenue vs competitors
How IOVA compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of +51.3% is the 2nd highest of 8, against a peer median of -8.2%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $4.13B USD | — | -36.4% | |
| LTM Jun 2026 | €2.64B EUR | -8.2% | -45.8% | |
| LTM Sep 2026 | $1.36B USD | +49.5% | +106.4% | |
| LTM Mar 2026 | $385.76M USD | +15.6% | +27.3% | |
| LTM Sep 2026 | $378.98M USD | +51.3% | — | |
| LTM Sep 2026 | $182.57M USD | +121.2% | +678.6% | |
| LTM Mar 2026 | $6.32M USD | -52.6% | -59.0% | |
| LTM Mar 2026 | $1M USD | -78.3% | +15.3% | |
| LTM Sep 2026 | $0 USD | -100.0% | — | |
| LTM Dec 2025 | $0 USD | — | — | |
| LTM Mar 2026 | $0 USD | — | — | |
| Peer median (excluding IOVA) | — | -8.2% | +15.3% | |
Competitors are the stored peer set for IOVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 1.19M | 164.07M | 263.5M |
| Cost of Revenue | 0 | 0 | 10.76M | 124M | 173.18M |
| Gross Profit | 0 | 0 | (9.57M) | 40.08M | 90.32M |
| Gross Margin | — | — | -804.5% | 24.4% | 34.3% |
| Research & Development | 259.04M | 294.78M | 344.08M | 282.34M | 300.27M |
| Selling, General & Admin | 83.66M | 104.1M | 106.92M | 153.02M | 152.32M |
| Operating Expenses | 342.7M | 398.88M | 450.99M | 435.35M | 488.53M |
| Depreciation & Amortization | 13.98M | 21.14M | 33.13M | 43.61M | 47.32M |
| EBITDA | (328.27M) | (371.77M) | (414.39M) | (331.4M) | (350.89M) |
| EBITDA Margin | — | — | -34851.9% | -202.0% | -133.2% |
| Operating Income | (342.7M) | (398.88M) | (460.56M) | (395.28M) | (398.21M) |
| Operating Margin | — | — | -38735.0% | -240.9% | -151.1% |
| Interest Income | 451K | 2.99M | 13.04M | 20.27M | 10.31M |
| Interest Expense | 0 | 2.99M | 0 | 0 | 0 |
| Other Income / Expenses | 451K | 2.99M | 13.04M | 20.27M | 5.16M |
| Income Before Tax | (342.25M) | (395.89M) | (447.52M) | (375.01M) | (393.05M) |
| Pre-Tax Margin | — | — | -37638.0% | -228.6% | -149.2% |
| Income Tax Expense | 0 | 0 | (3.48M) | (2.83M) | (2.07M) |
| Net Income | (342.25M) | (395.89M) | (444.04M) | (372.18M) | (390.98M) |
| Net Margin | — | — | -37345.4% | -226.8% | -148.4% |
| EPS (Basic) | (2.23) | (2.49) | (1.89) | (1.28) | (1.09) |
| EPS (Diluted) | (2.23) | (2.49) | (1.89) | (1.28) | (1.09) |
| Weighted Avg Shares | 153.41M | 159.26M | 235.13M | 289.88M | 357.35M |
| Weighted Avg Shares (Diluted) | 153.41M | 159.26M | 235.13M | 289.88M | 357.35M |
Iovance Biotherapeutics, Inc.
NASDAQ:IOVA
Intrinsic Alpha fair value
Locked
Current Price
$7.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.